Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

摘要: Abstract Background Intensive medical treatment increases resection rate of liver metastases in patients with metastatic colorectal cancer (MCRC). The effectiveness metastasectomies was evaluated MCRC who were treated previously reported FIr-B/FOx (triplet chemotherapy plus bevacizumab). Patients and Methods Fifty enrolled the phase II study classified according to involved sites (liver-only site, multiple sites) extent (single, multiple). Surgical resectability at baseline every 3 cycles treatment. metastases, activity, efficacy evaluated; progression-free survival (PFS) overall (OS) compared by using log-rank test. Results 33 50 consecutive unselected MCRC: limited, 22 patients; sites, 11 patients. Liver performed 13 patients: 26% MCRC, 39% MCRC. In liver-only a secondary surgery 54%: 6 9 single metastases. Also, 1 lung metastasectomy performed. Pathologic complete responses achieved 2 (15%). conversion unresectable 83%. Objective response rate, PFS, OS were, respectively: 84%, 23 months MCRC; 86%, 17 44 liver-limited PFS significantly increased Conclusion regimen may increase improve clinical outcome